Sotera Health Shares Are Priced 25% Lower Than Projected Future Cash Flow—Debt Concerns Highlight Increased Safety Margin
The article discusses how recent market volatility creates opportunities for value investors to find undervalued assets with a margin of safety. It highlights Sotera Health as a prime example, trading 25% below its projected future cash flow due to its essential healthcare services and strong competitive moat. However, the company's significant debt burden is noted as a key risk, emphasizing the importance of responsible financial management for long-term growth and compounding returns.
Capricorn Fund Managers Ltd Purchases New Shares in Sotera Health Company $SHC
Capricorn Fund Managers Ltd purchased 449,900 new shares of Sotera Health (NASDAQ:SHC) in Q4, valued at $7.94 million, making it their 15th biggest position. This acquisition comes after Sotera Health beat Q4 earnings expectations with $0.26 EPS and revenue of $303.44 million, and issued optimistic FY 2026 guidance. However, a significant insider sale by Director Gtcr Investment Xi LLC of 10 million shares for $152.7 million also occurred.
Sotera Health Company (NASDAQ:SHC) Receives Average Recommendation of "Moderate Buy" from Analysts
Sotera Health Company (NASDAQ:SHC) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month target price of $20.43. This comes after director GTCR Investment XI LLC sold a significant stake, reducing insider ownership, and the company reported exceeding Q4 earnings and revenue estimates. Despite recent insider selling, institutional investors have adjusted their holdings.
Sotera Health (SHC) records RSU tax-withholding for ex-SVP Dimitrief
Sotera Health Co (SHC) reported an insider equity event for former SVP, General Counsel, and Secretary Alexander Dimitrief. On March 31, 2026, 7,941 shares of common stock were withheld to cover tax obligations when 17,135 Restricted Stock Units (RSUs) vested upon his retirement. Following this transaction, Dimitrief directly holds 312,040 shares of Sotera Health common stock.
Assessing Sotera Health (SHC) Valuation After Earnings Beat And Upgraded Analyst Optimism
Sotera Health (SHC) recently reported strong Q4 net revenues, beating consensus estimates and boosting analyst optimism. While analysts indicate a fair value of $20.75 for SHC, suggesting it is undervalued, the company's current P/E ratio of 54.3x is significantly higher than the industry average, signaling potential valuation risk. Investors should consider the mixed signals from valuation, ongoing litigation, and growth expectations before making investment decisions.
Sotera Health (SHC) Soars 8.2%: Is Further Upside Left in the Stock?
Sotera Health's (SHC) stock jumped 8.2% after reporting strong fourth-quarter financial results, with net revenues up 5.7% and adjusted EBITDA increasing 8.2% in 2025. Despite the positive price movement, the consensus EPS estimate for the upcoming quarter has remained unchanged, and the article suggests investors monitor future earnings estimate revisions. Sotera Health currently holds a Zacks Rank #2 (Buy).
Barclays Maintains Sotera Health Company(SHC.US) With Buy Rating, Maintains Target Price $20
Barclays analyst Luke Sergott has reiterated a "buy" rating for Sotera Health Company (SHC.US) and maintained a target price of $20. According to TipRanks data, this analyst has a 33.8% success rate and an average return of -5.5% over the past year. The information is provided for informational purposes and does not constitute investment advice.
RBC Capital maintains Sotera Health stock rating on legal win
RBC Capital has reaffirmed an "Outperform" rating for Sotera Health (NASDAQ:SHC) and maintained a $24.00 price target following a favorable legal judgment in Georgia. This positive development significantly reduces the company's litigation settlement risk concerning ethylene oxide, leading RBC Capital to lower its implied settlement exposure to $122 million from $238 million. The firm believes that the reduction in legal overhang should support a re-rating of the stock's valuation, especially given its PEG ratio of 0.67 and current undervaluation based on Fair Value metrics.
Sotera Health (SHC) Jumps 8.2%: Does the Stock Have More Room to Rise?
Sotera Health (SHC) saw an 8.2% surge in its stock price, closing at $14.34, driven by strong fourth-quarter results including a 5.7% rise in net revenues and an 8.2% increase in adjusted EBITDA for 2025. The company is projected to report increased quarterly earnings and revenue, and currently holds a Zacks Rank #2 (Buy). However, continued gains may depend on upward revisions in earnings estimates, which have remained steady for the past month.
RBC Capital maintains Sotera Health stock rating on legal win
RBC Capital has reiterated an Outperform rating for Sotera Health (NASDAQ:SHC) with a $24.00 price target, following a favorable legal development in Georgia ethylene oxide litigation. The firm reduced its implied litigation settlement exposure and believes this will support a re-rating in the company's valuation multiple. Sotera Health recently reported strong Q4 2025 earnings, exceeding analyst expectations, and has had changes to its board, with a secondary offering of shares from private equity firms.
Sotera Health Company (NASDAQ:SHC) Short Interest Up 19.4% in March
Sotera Health Company (NASDAQ:SHC) experienced a significant increase in short interest in March, rising 19.4% to over 10.5 million shares, representing 8.3% of the stock. Despite a director's sale of 10 million shares, insiders still own 55.12% and institutional investors hold 91.03% of the company. Sotera Health also beat quarterly earnings estimates and issued positive FY2026 guidance, with analysts setting a consensus target price of $20.43.
Sotera Health Co (SHC) Stock Price Up 6.95% on Mar 31
Sotera Health Co (SHC) saw its stock price rise by 6.95% to $14.16 on March 31, currently trading 28.66% below its 52-week high and 48.58% above its 52-week low. Eight analysts provided an average one-year target price of $20.75, implying a 46.54% upside, while GuruFocus estimates a fair value of $17.38, indicating a 22.74% upside. The consensus recommendation from 11 brokerage firms for SHC is "Outperform."
Exchange Traded Concepts LLC Takes $7.74 Million Position in Sotera Health Company $SHC
Exchange Traded Concepts LLC recently acquired a new position of 438,707 shares in Sotera Health Company (SHC), valued at approximately $7.74 million. This move represents 0.15% of the company's holdings, alongside other institutional investors adjusting their stakes. The company reported slightly better-than-expected Q4 earnings, with a "Moderate Buy" consensus rating and a target price of $20.43 from analysts, despite a significant insider share sale.
Nordea Investment Management Buys Stake in Sotera Health
Nordea Investment Management AB has acquired a new stake in Sotera Health Company, purchasing 107,822 shares worth $1.9 million in the fourth quarter of 2025. This investment reflects growing institutional interest in Sotera Health, a global provider of sterilization, lab testing, and advisory services for the medical device, pharmaceutical, and consumer products industries. The acquisition further strengthens Sotera Health's institutional ownership, which now accounts for over 91% of its stock.
Nordea Investment Management AB Makes New Investment in Sotera Health Company $SHC
Nordea Investment Management AB has made a new investment in Sotera Health Company (NASDAQ:SHC), acquiring 107,822 shares valued at approximately $1.91 million in Q4. This adds to Sotera Health's significant institutional ownership of about 91.03%, despite a recent insider sale by GTCR. The company also reported strong Q4 earnings, beating revenue and EPS expectations, and analysts currently have a "Moderate Buy" consensus rating with a $20.43 price target.
Is It Time To Reconsider Sotera Health (SHC) After Recent Share Price Weakness?
Sotera Health (SHC) has experienced recent share price weakness, with a 25.8% decline year to date. A Discounted Cash Flow (DCF) analysis suggests the stock might be undervalued by 32.9% at $19.56 per share compared to its current price of US$13.13. However, its Price/Earnings (P/E) ratio of 47.91x is higher than the industry average and Simply Wall St's Fair Ratio of 24.98x, indicating it could be overvalued on an earnings multiple basis.
Q4 Rundown: Sotera Health Company (NASDAQ:SHC) Vs Other Research Tools & Consumables Stocks
This article reviews the Q4 performance of several research tools & consumables stocks, highlighting Sotera Health Company, Bio-Techne, Mettler-Toledo, Revvity, and Thermo Fisher. Sotera Health exceeded revenue expectations and raised its full-year guidance, though its stock price dipped post-earnings. The article also touches on broader market dynamics, including shifts from AI and crypto to geopolitical risks.
Sotera Health Co Stock: Essential Sterilization Leader with Positive Credit Outlook Boost
Sotera Health Co, a leader in medical device sterilization and lab testing, received a positive credit outlook revision from Moody's, affirming its B1 CFR on March 26, 2026. This reflects improved financial metrics and operational execution, boosting investor confidence in its debt management and expansion efforts. The company's essential services in regulated industries, coupled with its multi-segment structure and competitive edge in sterilization technologies, position it as a stable investment opportunity, particularly for North American investors seeking defensive healthcare plays.
Vanguard disaggregates holdings; Sotera Health (SHC) shows 0% ownership
Vanguard Group has filed an amended Schedule 13G for Sotera Health Co (SHC), reporting 0% beneficial ownership of the company's common stock. This change follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries now report their holdings separately. The filing confirms Vanguard has no voting or dispositive power over SHC shares and no other single person holds more than 5% of the reported securities.
Sotera Health Defeats Former Executive’s $13 Million Lawsuit
Sotera Health Co. successfully defended itself in a Delaware Chancery Court against a lawsuit brought by a former vice president seeking $13.2 million. The executive had quit after a demotion, alleging the company and its private equity sponsors deliberately structured transactions to avoid triggering payouts to him. The court sided with Sotera, finding no such deliberate avoidance of vesting criteria.
Q4 Rundown: Sotera Health Company (NASDAQ:SHC) Vs Other Research Tools & Consumables Stocks
This article provides a Q4 rundown of Sotera Health Company (NASDAQ:SHC) and other research tools & consumables stocks, highlighting their financial performance and market reception. Sotera Health exceeded analysts' expectations with strong revenues and a positive outlook, despite a subsequent stock dip. The article also reviews top performers like Bio-Techne and notes the weakest, Mettler-Toledo, while touching on broader market shifts driven by AI and geopolitical events.
Sotera Health Defeats Former Executive’s $13 Million Lawsuit
Sotera Health Co. has won a lawsuit filed by a former vice president, Kurt Roth, who sought $13.2 million after resigning due to a demotion. A Delaware Chancery Court judge ruled that Sotera and its private equity sponsors did not deliberately structure transactions to avoid payouts to Roth, even though they were aware of the vesting criteria.
Q4 Rundown: Sotera Health Company (NASDAQ:SHC) Vs Other Research Tools & Consumables Stocks
This article provides a Q4 rundown of research tools & consumables stocks, focusing on Sotera Health Company (SHC) and comparing its performance to peers like Bio-Techne (TECH), Mettler-Toledo (MTD), Revvity (RVTY), and Thermo Fisher (TMO). Sotera Health exceeded revenue and EPS guidance, performing strongly despite a subsequent stock dip. The sector as a whole met revenue expectations but has seen share price declines post-earnings.
Q4 Research Tools & Consumables Earnings: Bio-Techne (NASDAQ:TECH) Earns Top Marks
Bio-Techne (NASDAQ:TECH) received top marks in the Q4 earnings season for research tools and consumables stocks, reporting revenues of $295.9 million, exceeding analyst expectations. Despite strong performance and a "stabilizing operating environment," its stock is down 18.5%. The article also reviews other companies like Revvity, Mettler-Toledo, Sotera Health Company, and Agilent, highlighting their Q4 results and stock performance reactions.
StockStory Analysis: 3 Stocks with High Targets but Underlying Weaknesses - News and Statistics
A StockStory analysis has identified three companies—Sotera Health (SHC), Latham (SWIM), and Terex (TEX)—that, despite having favorable consensus targets, show underlying weaknesses. Sotera Health exhibits modest growth and flat earnings, Latham struggles with subpar operating margins and free cash flow, and Terex faces muted revenue growth and contracting earnings per share. The report advises caution for investors considering these stocks due to their fundamental performance issues.
Sotera Health (SHC) Encounters $16.40 Ceiling as Earnings Strength and Grant Story Drive Breakout Prospects
Sotera Health (SHC) is showing a strong upward trend, trading near its yearly high, but facing resistance at $16.40. The company's robust Q4 2025 earnings, increased 2026 revenue guidance, and a recently awarded grant are providing fundamental support for a potential breakout. However, significant risks like a high net leverage ratio and stock volatility could cap its bullish outlook.
A $175 Million Move Into Sotera Health Signals Potential Opportunity Amid 21% Stock Drop
Sessa Capital significantly increased its stake in Sotera Health (SHC) by over 10.6 million shares, representing an estimated $175.80 million investment, despite a recent 21% stock drop. This move suggests Sessa Capital sees potential opportunity in Sotera Health, which provides sterilization and lab testing services, believing the current dip is due to litigation risks, high leverage, and market oversupply rather than underlying fundamental weaknesses. The firm has a history of investing in companies with strong fundamentals facing controversy, indicating a long-term belief in Sotera's growth capabilities.
A $175 Million Investment in Sotera Health Suggests Possible Opportunity Following 21% Share Decline
Sessa Capital has made a significant investment of $175.8 million in Sotera Health (NASDAQ:SHC), acquiring over 10.6 million shares and making it nearly 7% of their AUM. This move comes despite recent stock pressures on Sotera Health due to litigation, debt, and regulatory challenges. The investment suggests Sessa Capital sees potential in the company's strong fundamentals and consistent growth, believing the current market sentiment disconnect may be temporary.
Sotera Health CFO Says Growth Story Intact, Sees 2026 Organic Growth of 5%-6.5% at KeyBanc Forum
Sotera Health's CFO, Jon Lyons, affirmed the company's growth trajectory at the KeyBanc Healthcare Forum, projecting 5%-6.5% constant-currency organic growth for 2026. Lyons highlighted strong 2025 performance driven by Sterigenics' volume growth and sustained EBITDA margins above 50%, despite headwinds in Nelson Labs. The company is focused on free cash flow generation, targeting $500-$600 million over three years, with CapEx expected to significantly decrease in 2027.
SHC Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of Sotera Health Co (SHC), detailing its revenue streams, profitability margins, and a comparison with competitors. SHC generates most of its revenue from Sterigenics, which accounts for 61.9% of its total sales. The company exhibits solid profitability with a gross margin of 53.68%, an operating margin of 34.73%, and a net margin of 11.48%.
An Institution Increases Holdings in Sotera Health Against the Trend
Inherent Management Corp. significantly increased its stake in Sotera Health Company (SHC) during Q4, purchasing 200,050 shares worth approximately $3.31 million. This move is notable because Sotera Health has underperformed the S&P 500 and faces market concerns despite solid fundamentals and consistent revenue growth. The conviction shown by Inherent Management Corp., with SHC representing over 10% of its 13F assets, suggests confidence in the company's long-term prospects despite external pressures.
Inherent Management Corp. Increases Stake in Sotera Health by $3.31 Million
Inherent Management Corp. significantly increased its stake in Sotera Health during Q4 2026 by acquiring 200,050 shares, an estimated $3.31 million investment, demonstrating strong confidence in the healthcare services company. Sotera Health now accounts for 10.6% of Inherent's 13F assets, despite a 23% decline in its share price last year. The company reported robust 6% revenue growth, reaching $1.16 billion, though investor sentiment remains cautious due to litigation risks and regulatory scrutiny.
Investment Firm Boosts Holdings in Sterilization Provider Sotera Health - News and Statistics
Inherent Management Corp. has increased its stake in Sotera Health Company by acquiring an additional 200,050 shares, valued at approximately $3.31 million, in the fourth quarter. This acquisition has brought Sotera Health's representation in the investment manager's portfolio to 10.6%, making it the fifth-largest holding. Despite the company's consistent revenue growth and recent share price increase over the past year, its stock has declined since the last quarter's end due to ongoing investor concerns regarding litigation and other factors.
Sotera Health Shares Down 24% This Year. Is the Stock a Buy as One Investor Reveals Adding $3 Million More?
Inherent Management Corp. recently increased its stake in Sotera Health (NASDAQ:SHC) by buying an additional 200,050 shares, valued at approximately $3.31 million. This purchase raised Sotera Health's representation to 10.62% of the fund's assets under management, signaling strong conviction despite the stock underperforming the S&P 500 and being down 24% year-to-date. The company continues to show stable fundamentals with 20 consecutive years of revenue growth, though litigation concerns and leverage weigh on its market perception.
Sotera Health Co (SHC) director Kenneth D. Krause files initial Form 3
Sotera Health Co (SHC) director Kenneth D. Krause has filed an initial Form 3, which is an insider ownership report, to register his status as a reporting insider. The filing indicates no current transactions or holdings, primarily serving to establish his reporting obligations under SEC rules. This ensures that any future transactions by Mr. Krause will be transparently reported.
Sotera Health Stock Drops 24% in 2024. Should You Invest After an Investor Increases Their Stake by $3 Million?
Inherent Management Corp. recently increased its stake in Sotera Health (NASDAQ: SHC) by acquiring 200,050 shares, valuing the transaction at approximately $3.31 million. This move makes Sotera Health 10.6% of Inherent Management Corp.'s 13F assets under management, signaling strong confidence despite a 23% stock drop in the last quarter due to litigation and regulatory concerns. The article discusses Sotera Health's financial performance, its role in healthcare supply chains, and whether investors should consider it, noting The Motley Fool Stock Advisor did not include it in their top picks.
Reflecting on the Fourth Quarter Financial Results of Research Tools & Consumables Companies: Sotera Health Company (NASDAQ:SHC)
This article reviews the fourth-quarter financial performance of companies in the research tools and consumables industry, focusing on Sotera Health Company (NASDAQ:SHC). Despite Sotera Health beating revenue and EPS estimates, its stock dropped 21.4% post-earnings, reflecting higher investor expectations. The report also covers other key players like Bio-Techne, Mettler-Toledo, Avantor, and Bruker, noting a general trend of solid Q4 performance but negative stock reactions, and discusses shifting market sentiments from AI concerns to geopolitical risks.
Sotera Health (SHC) loses 13% in 4 weeks, here's why a trend reversal may be around the corner
This article analyzes why Sotera Health (SHC) has fallen 13% in four weeks and suggests a potential trend reversal is imminent. It likely delves into financial indicators, market sentiment, or recent company news that could signal a turnaround for the stock. The piece aims to provide insights into future performance based on current downturns.
Sotera Health Company $SHC Position Raised by Voss Capital LP
Voss Capital LP significantly increased its stake in Sotera Health Company (NASDAQ:SHC) by 146.7% in the third quarter, now holding 1.85 million shares valued at $29.1 million. This makes SHC its 19th largest position, accounting for approximately 1.4% of the fund's portfolio, despite recent insider selling by GTCR. The company maintains a "Moderate Buy" consensus rating from analysts, with a target price of $20.43, and recently surpassed quarterly EPS and revenue estimates, issuing positive FY2026 guidance.
Sotera Health Co Stock (ISIN: US8293551086) Holds Steady Amid Sterilization Sector Resilience and Healthcare Demand Tailwinds
Sotera Health Co (ISIN: US8293551086) stock is exhibiting limited volatility, reflecting its strong position in medical device sterilization and lab testing services. The company benefits from stable demand in healthcare, its recession-resistant business model, and operational efficiencies, appealing to investors seeking long-term growth and defensive qualities. Despite no major recent announcements, the stock's stability is supported by its essential services, robust financial performance, and strategic capital allocation, with potential catalysts including capacity expansions and M&A.
Sotera Health Company (NASDAQ:SHC) Sees Significant Growth in Short Interest
Sotera Health Company (NASDAQ:SHC) experienced a 15.1% increase in short interest in February, totaling 8,825,205 shares, which represents 6.9% of its float and 5.5 days-to-cover. Despite significant insider selling by Director GTCR Investment XI LLC, the company recently beat quarterly earnings estimates and provided positive FY2026 EPS guidance. Analysts currently rate SHC as a "Moderate Buy" with a consensus price target of $20.43.
Kenneth Krause joins Sotera Health (NASDAQ: SHC) board, audit committee
Sotera Health (NASDAQ: SHC) announced that Kenneth D. Krause has been appointed as a Class I director to its Board, effective March 16, 2026. He will also serve on the company's Audit Committee and Litigation Committee. This appointment follows the resignation of Constantine S. Mihas, which the company stated was due to a reduction in designated directors and not any disagreement with the company's operations or policies.
Irenic Capital Management LP Sells 163,940 Shares of Sotera Health Company $SHC
Irenic Capital Management LP reduced its stake in Sotera Health Company (NASDAQ:SHC) by 4.4% in Q3 2025, selling 163,940 shares but still maintaining it as its largest position. Concurrently, a director, GTCR Investment XI LLC, sold 10 million shares, significantly cutting its holdings. Sotera Health recently reported strong Q4 results, beating EPS and revenue estimates, and provided positive FY2026 guidance.
Sotera Health appoints Kenneth Krause to board of directors
Sotera Health Company (SHC) has announced the appointment of Kenneth D. Krause as an independent director to its Board of Directors. Krause currently serves as Executive Vice President and CFO of Rollins (ROL). The change in the board comes as Constantine Mihas resigns, effective March 16, 2026, due to a reduction in designated director seats for certain stockholders.
Sotera Health appoints Kenneth Krause to board of directors
Sotera Health Company has appointed Kenneth D. Krause as an independent director to its board. Krause, currently the Executive Vice President and Chief Financial Officer of Rollins, Inc., brings extensive financial expertise and will serve on Sotera Health's Audit and Litigation Committees. His appointment follows the resignation of Constantine (Dean) S. Mihas due to a reduction in designated director seats.
Sotera Health appoints Kenneth D. Krause to board following director resignation
Sotera Health (NASDAQ:SHC) announced the resignation of Constantine S. Mihas from its board of directors and the appointment of Kenneth D. Krause as a Class I director. Krause, Executive Vice President and CFO of Rollins, Inc., will serve on the Audit and Litigation Committees. This appointment follows recent strong fourth-quarter earnings for Sotera Health, which surpassed analyst expectations.
Sotera Health Shares Rise 18% in a Year. Here's What a $37 Million Stake Trim Signals
MIG Capital reduced its stake in Sotera Health by selling over 2.2 million shares valued at $37.41 million in Q4, though it remains a significant holding for the firm. Despite this trim, Sotera Health shares have risen 18% over the past year and the company reported its 20th consecutive year of revenue growth, with strong projected growth for 2026. The transaction is viewed as routine portfolio management rather than a lack of conviction, given Sotera's consistent performance.
Pest-control CFO joins Sotera Health board as director Mihas exits
Sotera Health has appointed Kenneth D. Krause, CFO of Rollins, Inc., as a new independent director to its Board, effective March 16, 2026. Krause brings extensive experience in corporate strategy, capital allocation, and public company governance, and will serve on the Audit and Litigation Committees. Concurrently, Constantine S. Mihas resigned from the Board due to a reduction in designated director positions by certain stockholders.
Sotera Health Appoints Kenneth D. Krause to the Board of Directors
Sotera Health Company announced the appointment of Kenneth D. Krause as a new independent director to its Board of Directors. Mr. Krause, currently Executive Vice President and CFO of Rollins, Inc., brings extensive experience in corporate strategy, capital allocation, and public company governance. Constantine S. Mihas resigned from the Board, effective March 16, 2026, due to a reduction in designated director numbers.
Sotera Health Appoints Kenneth D. Krause to the Board of Directors
Sotera Health Company has appointed Kenneth D. Krause as a new independent director to its Board. Mr. Krause, current Executive Vice President and CFO of Rollins, Inc., brings extensive experience in corporate strategy, capital allocation, and public company governance. He will serve on the Audit and Litigation Committees, replacing Constantine S. Mihas, who resigned due to a reduction in designated director seats.
